Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Spesolimab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Boehringer Ingelheim
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.
- 22 Jan 2019 Planned initiation date changed from 14 Jan 2019 to 5 Feb 2019.
- 09 Jan 2019 Planned initiation date changed from 4 Jan 2019 to 14 Jan 2019.